United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Shares of Pfizer Inc and U.S.-listed shares of partner BioNTech SE rose on Friday after they released additional data for their experimental coronavirus vaccine and reiterated they were on track to seek a regulatory review in October.

Pfizer, BioNTech shares gain as more data backs vaccine candidate

Pfizer Inc (NYSE: PFE), and its partner BioNTech SE (NASDAQ: BNTX), announced positive results for the Phase 1 trial of their second COVID-19 vaccine candidate, stating that the latest vaccine candidate had fewer side effects than their first.

Pfizer, BioNTech Say Second Coronavirus Vaccine Shows Fewer Side Effects Than Their First Candidate

AstraZeneca

Moderna

Coronavirus vaccine companies are attacking the virus and have late-stage trials underway. But the Covid vaccine timeline may not be what you think.

Coronavirus Vaccine Companies Target Best-Case Timeline — But What's The Worst Case?

Pfizer and BioNTech surprised many industry watchers on July 27 when they announced they would conduct a large-scale study of a vaccine for Covid-19. The surprise?

Pfizer and BioNTech's favored Covid-19 vaccine has fewer side effects than their first

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and immunogenicity data from their ongoing U.S.

Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19

Johnson & Johnson

Merck

What’s the best way for investors to gain diversified exposure to today's leading vaccine research? Here he recommends a 5-stock portfolio to boost your chances to benefit from potential progress made toward a successful Covid vaccine.

This 5-Stock Portfolio Is A Safe Bet On A Future COVID-19 Vaccine

Its coronavirus vaccine effort is grabbing headlines, but this company isn't a one-trick pony.

Why Is Everyone Talking About Pfizer?

CureVac B.V

Inovio Pharmaceuticals

Novavax

Hope for a successful vaccine by the winter is fueling trials at a record pace.

COVID-19: The Real Results Are A Long Way Away

Roche’s ADR has gained over 20% since the March 23 lows of this year, while Pfizer stock has fared much better and gained 35% of its value. The lockdown in various parts of the world has had a negative impact on the pharmaceuticals industry worldwide due to deferment of elective surgeries and fewer.

Pfizer Stock Could See More Upside Compared To Roche

Aflac

Con Ed

General Dynamics

People's United Financial

AT&T

Vanguard S&P 500 ETF

Vanguard High Dividend Yield ETF

Walgreens

Dividend Stock Purchases: Bert's July Summary

You don't hear much about these products. But they're quietly making Pfizer a lot of money.

Pfizer's Unheralded Franchise That's Worth Billions of Dollars

Vaccine candidates need to garner regulatory approval by Jan. 31, 2021, or else.

Moderna and Other Coronavirus Vaccine Makers to Take Reduced Payments If Approval Milestones Not Met

The federal government will foot the bill for vaccines, while insurers and the CARES Act will cover the cost of administering them.

Coronavirus Vaccine Will Be Free for Americans, Says HHS Official

GlaxoSmithKline

Sanofi

The U.S. has doled out billions to develop a vaccine against the coronavirus, locking in a minimum of 800 million doses so far.

The U.S. has already invested billions on potential coronavirus vaccines. Here's where the deals stand

Why Pfizer's 4% Yield Is Your Best Covid-19 Vaccine Play

Becton, Dickinson and Co.

Thermo Fisher Scientific

High costs make drug developers unlikely picks for the Oracle of Omaha.

Why Warren Buffett Might Not Be Crazy About Biopharma Stocks

Amgen

Gilead Sciences

The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.

US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch

AbbVie

Eli Lilly

Novartis

Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes

It's a tight schedule, but it could mean the duo gains regulatory approval first.

BioNTech and Pfizer Hope to Have Late-Stage Coronavirus Vaccine Results by October

BioNTech Chief Ugur Sahin says the recent start of Phase 3 testing of the company's coronavirus vaccine candidate "put us in a position to seek regulatory review as early as October."

Covid Report: BioNTech Says It Could Seek Vaccine OK By October

A leading vaccine candidate could lift Pfizer stock into the first sustained uptrend since 2018.

Pfizer (PFE) Could Enter New Uptrend

Success with a coronavirus vaccine candidate could push this big pharma stock through the roof.

Should Pfizer Be Your Next Coronavirus Buy?

COVID-19 has weakened the US economy more than China's.

T Cell Responses To Coronavirus Vaccines Are In The Interest Of National Security

The pharma titan's experimental COVID-19 vaccine caught investors' eyes last month.

Why Pfizer Stock Bolted Higher in July

Dynavax Technologies

Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.

News for Pfizer Stock (PFE)